Huan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Huan Zhang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Jiangjiang Zhu
The Ohio State University
16 shared publications - Adaliz Torres-Rosado
The Ohio State University Wexner Medical Center 1 Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition Columbus, Ohio
14 shared publications - Alexus Liette
The Ohio State University Wexner Medical Center 1 Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition Columbus, Ohio
14 shared publications - Andrew Gold
The Ohio State University 2 The Comprehensive Cancer Center Columbus, Ohio
14 shared publications - Ericka Vélez-Bonet
The Ohio State University Wexner Medical Center 1 Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition Columbus, Ohio
14 shared publications - Fouad Choueiry
The Ohio State University 2 The Comprehensive Cancer Center Columbus, Ohio
14 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Macronutrient composition and ingredient content of experimental diets, including matched low-fat controls for HFD, DIO, and KD formulations.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Macronutrient composition and ingredient content of experimental diets, including matched low-fat controls for HFD, DIO, and KD formulations.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pancreas weight in control and KrasG12D mice across dietary conditions, demonstrating a decrease following KD.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pancreas weight in control and KrasG12D mice across dietary conditions, demonstrating a decrease following KD.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Representative H&E liver histology showing genotype-dependent differences between control and KrasG12D mice under varying dietary fat conditions.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Representative H&E liver histology showing genotype-dependent differences between control and KrasG12D mice under varying dietary fat conditions.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Tumor growth, body weight, glucose tolerance, and ketone levels in a non-obese orthotopic PDAC model, showing no effect of KD on tumor growth.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Tumor growth, body weight, glucose tolerance, and ketone levels in a non-obese orthotopic PDAC model, showing no effect of KD on tumor growth.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pancreatic β-hydroxybutyrate concentrations in KrasG12D mice across diet groups following KD intervention.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pancreatic β-hydroxybutyrate concentrations in KrasG12D mice across diet groups following KD intervention.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pancreatic lesion severity in KrasG12D mice selected for metabolomic analysis across diet groups.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pancreatic lesion severity in KrasG12D mice selected for metabolomic analysis across diet groups.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
KD effects in an orthotopic PDAC model, showing no inhibition of tumor growth regardless of weight loss.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
KD effects in an orthotopic PDAC model, showing no inhibition of tumor growth regardless of weight loss.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Glucose tolerance by AUC at baseline and after 15 weeks, showing increased glucose intolerance following DIO compared to LFD.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Glucose tolerance by AUC at baseline and after 15 weeks, showing increased glucose intolerance following DIO compared to LFD.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pathological distribution and disease burden indicating suppression of PDAC development by KD in obesity-associated models.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pathological distribution and disease burden indicating suppression of PDAC development by KD in obesity-associated models.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor outcomes. Obesity increases the risk of PDAC through metabolic dysregulation and inflammation. Ketogenic diet (KD) can alter metabolism and has been evaluated for its effects on tumor progression in nonobese PDAC using genetically engineered mouse models (GEMM). We hypothesized that KD may also prevent obesity-associated PDAC progression by altering body composition and cancer metabolism. Therefore, male PDAC GEMMs were subjected to diet-induced obesity (DIO) using high-fat diets or maintained on a low-fat diet (LFD) for 15 weeks. Mice were then randomized to continue the initial diets or switch to a KD or matched control diet for 6 weeks. Body weight and composition, glucose tolerance, ketone levels, pancreas histology, and tissue metabolomics were assessed. Furthermore, murine pancreas-derived organoids from DIO or LFD-fed GEMMs were treated with a ketone body and analyzed using untargeted metabolomics. In obese PDAC GEMMs, KD delayed cancer progression independent of weight loss, an effect not observed in nonobese LFD-fed mice. KD-mediated PDAC suppression was associated with enrichment of pancreatic metabolic pathways that support nonglucose energy production. Ketone-treated organoids recapitulated a subset of the KD-associated metabolic differences observed in vivo, suggesting a direct metabolic effect on cancer cells. These findings suggest potential benefits of a KD in preventing obesity-associated PDAC. The diet–cancer metabolic interactions highlight potential opportunities for dietary or metabolic interventions to prevent PDAC in high-risk obese populations. Significance:Ketogenic diet prevents pancreatic cancer progression in obese, but not in nonobese, genetically engineered mouse models and modifies pancreatic metabolic pathways, informing future dietary and therapeutic strategies for high-risk obese populations.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ketogenic Diet Prevents Obesity-Associated Pancreatic Cancer Independent of Weight Loss and Induces Pancreatic Metabolic Reprogramming
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor outcomes. Obesity increases the risk of PDAC through metabolic dysregulation and inflammation. Ketogenic diet (KD) can alter metabolism and has been evaluated for its effects on tumor progression in nonobese PDAC using genetically engineered mouse models (GEMM). We hypothesized that KD may also prevent obesity-associated PDAC progression by altering body composition and cancer metabolism. Therefore, male PDAC GEMMs were subjected to diet-induced obesity (DIO) using high-fat diets or maintained on a low-fat diet (LFD) for 15 weeks. Mice were then randomized to continue the initial diets or switch to a KD or matched control diet for 6 weeks. Body weight and composition, glucose tolerance, ketone levels, pancreas histology, and tissue metabolomics were assessed. Furthermore, murine pancreas-derived organoids from DIO or LFD-fed GEMMs were treated with a ketone body and analyzed using untargeted metabolomics. In obese PDAC GEMMs, KD delayed cancer progression independent of weight loss, an effect not observed in nonobese LFD-fed mice. KD-mediated PDAC suppression was associated with enrichment of pancreatic metabolic pathways that support nonglucose energy production. Ketone-treated organoids recapitulated a subset of the KD-associated metabolic differences observed in vivo, suggesting a direct metabolic effect on cancer cells. These findings suggest potential benefits of a KD in preventing obesity-associated PDAC. The diet–cancer metabolic interactions highlight potential opportunities for dietary or metabolic interventions to prevent PDAC in high-risk obese populations. Significance:Ketogenic diet prevents pancreatic cancer progression in obese, but not in nonobese, genetically engineered mouse models and modifies pancreatic metabolic pathways, informing future dietary and therapeutic strategies for high-risk obese populations.